{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:42:45Z","timestamp":1784054565462,"version":"3.55.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Patients with idiopathic inflammatory myopathies (IIM) have severe vascular involvement, which contributes to disease morbidity and mortality. Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL) associated protein that protects the vascular endothelium from oxidative injury and damage. The current work assessed the functional and genetic determinants of PON1 activity in IIM patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 184 IIM patients and 112 healthy controls (HC) were included. PON1 enzyme activity was assessed by paraoxonase, arylesterase and lactonase assays, and the Q192R PON1 single nucleotide polymorphism (SNP) was analysed. Multivariate regression models examined associations of PON1 activity with IIM diagnosis and myositis disease outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The arylesterase and lactonase activities of PON1 were significantly lower in IIM patients compared with HC. Higher myositis disease activity, the presence of severe IIM-associated interstitial lung disease (ILD), and the presence of MDA5 or anti-synthetase antibodies were significantly associated with lower PON1 activity. The PON1 Q192R polymorphism was strongly linked to the paraoxonase activity of PON1 in IIM, and patients with the PON1 QQ genotype had better IIM disease outcomes compared with patients with the QR or RR genotypes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The arylesterase and lactonase activities of PON1 are significantly impaired in IIM patients compared with HC, and inversely associate with IIM disease activity and the presence of severe ILD. The PON1 QQ genotype associates with more favourable disease outcomes in IIM patients. Large prospective studies are needed to further evaluate the role of PON1 and PON1 genetic polymorphisms in the development and propagation of IIM and IIM-ILD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab795","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T12:01:09Z","timestamp":1634904069000},"page":"2512-2523","source":"Crossref","is-referenced-by-count":9,"title":["Abnormal paraoxonase-1 (PON1) enzyme activity in idiopathic inflammatory myopathies"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7216-7219","authenticated-orcid":false,"given":"Sangmee Sharon","family":"Bae","sequence":"first","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ani","family":"Shahbazian","sequence":"additional","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Golub","sequence":"additional","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buzand","family":"Oganesian","sequence":"additional","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Dowd","sequence":"additional","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Vayngortin","sequence":"additional","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Elashoff","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasa T","family":"Reddy","sequence":"additional","affiliation":[{"name":"Health Services Research and Cardiology, Department of Medicine, David Geffen School of Medicine, UCLA , Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Charles-Schoeman","sequence":"additional","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,26]]},"reference":[{"key":"2022072312084583300_keab795-B1","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","article-title":"Polymyositis, dermatomyositis and inclusion-body myositis","volume":"325","author":"Dalakas","year":"1991","journal-title":"N Engl J Med"},{"key":"2022072312084583300_keab795-B2","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/acr.22520","article-title":"Traditional cardiovascular risk factors and coronary artery calcification in adults with polymyositis and dermatomyositis: a Danish multicenter study","volume":"67","author":"Diederichsen","year":"2015","journal-title":"Arthritis Care Res"},{"key":"2022072312084583300_keab795-B3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/annrheumdis-2017-211402","article-title":"Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study","volume":"77","author":"Dobloug","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022072312084583300_keab795-B4","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s11926-996-0024-4","article-title":"Pathogenesis of idiopathic inflammatory myopathies","volume":"8","author":"Grundtman","year":"2006","journal-title":"Curr Rheumatol Rep"},{"key":"2022072312084583300_keab795-B5","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ana.410270402","article-title":"Microvascular changes in early and advanced dermatomyositis: a quantitative study","volume":"27","author":"Emslie-Smith","year":"1990","journal-title":"Ann Neurol"},{"key":"2022072312084583300_keab795-B6","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0022-2275(20)33462-3","article-title":"Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3","volume":"41","author":"Navab","year":"2000","journal-title":"J Lipid Res"},{"key":"2022072312084583300_keab795-B7","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0022-2275(20)33461-1","article-title":"Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1","volume":"41","author":"Navab","year":"2000","journal-title":"J Lipid Res"},{"key":"2022072312084583300_keab795-B8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.plipres.2015.08.003","article-title":"Effect of statin therapy on paraoxonase-1 status: a systematic review and meta-analysis of 25 clinical trials","volume":"60","author":"Ferretti","year":"2015","journal-title":"Prog Lipid Res"},{"key":"2022072312084583300_keab795-B9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.atherosclerosis.2006.05.027","article-title":"Aspirin is a substrate for paraoxonase-like activity: implications in atherosclerosis","volume":"191","author":"Santanam","year":"2007","journal-title":"Atherosclerosis"},{"key":"2022072312084583300_keab795-B10","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00125-003-1065-0","article-title":"Aspirin use is associated with higher serum concentrations of the anti-oxidant enzyme, paraoxonase-1","volume":"46","author":"Blatter-Garin","year":"2003","journal-title":"Diabetologia"},{"key":"2022072312084583300_keab795-B11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1021\/jm990436t","article-title":"Selective plasma hydrolysis of glucocorticoid gamma-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism","volume":"43","author":"Biggadike","year":"2000","journal-title":"J Med Chem"},{"key":"2022072312084583300_keab795-B12","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.299.11.1265","article-title":"Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk","volume":"299","author":"Bhattacharyya","year":"2008","journal-title":"JAMA"},{"key":"2022072312084583300_keab795-B13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.atherosclerosis.2010.11.028","article-title":"Four genetic polymorphisms of paraoxonase gene and risk of coronary heart disease: a meta-analysis based on 88 case-control studies","volume":"214","author":"Wang","year":"2011","journal-title":"Atherosclerosis"},{"key":"2022072312084583300_keab795-B14","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022072312084583300_keab795-B15","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"2022072312084583300_keab795-B16","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1002\/acr.20532","article-title":"Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and patient\/parent global activity, manual muscle testing (MMT), health assessment questionnaire (HAQ)\/childhood health assessment questionnaire (C-HAQ), childhood myositis assessment scale (CMAS), myositis disease activity assessment tool (MDAAT), disease activity score (das), short form 36 (SF-36), child health questionnaire (CHQ), physician global damage, myositis damage index (mdi), quantitative muscle testing (QMT), myositis functional index-2 (fi-2), myositis activities profile (MAP), inclusion body myositis functional rating scale (IBMFRS), cutaneous dermatomyositis disease area and severity index (CDASI), cutaneous assessment tool (CAT), dermatomyositis skin severity index (DSSI), skindex, and dermatology life quality Index (DLQI","volume":"63(Suppl 11","author":"Rider","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2022072312084583300_keab795-B17","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2022072312084583300_keab795-B18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1183\/09059180.00002114","article-title":"Staging of idiopathic pulmonary fibrosis: past, present and future","volume":"23","author":"Kolb","year":"2014","journal-title":"Eur Respir Rev"},{"key":"2022072312084583300_keab795-B19","doi-asserted-by":"crossref","first-page":"16848","DOI":"10.1038\/s41598-020-74016-w","article-title":"Suppression of inflammatory arthritis in human serum paraoxonase 1 transgenic mice","volume":"10","author":"Charles-Schoeman","year":"2020","journal-title":"Sci Rep"},{"key":"2022072312084583300_keab795-B20","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1002\/art.38118","article-title":"Association of paraoxonase 1 gene polymorphism and enzyme activity with carotid plaque in rheumatoid arthritis","volume":"65","author":"Charles-Schoeman","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2022072312084583300_keab795-B21","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.arcmed.2012.08.012","article-title":"Human plasma paraoxonase 1 (PON1) arylesterase activity during aging: correlation with susceptibility of LDL oxidation","volume":"43","author":"Mehdi","year":"2012","journal-title":"Arch Med Res"},{"key":"2022072312084583300_keab795-B22","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3164\/jcbn.18-73","article-title":"Sex difference: an important issue to consider in epidemiological and clinical studies dealing with serum paraoxonase-1","volume":"64","author":"Trentini","year":"2019","journal-title":"J Clin Biochem Nutr"},{"key":"2022072312084583300_keab795-B23","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1161\/01.ATV.0000096207.01487.36","article-title":"Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2","volume":"23","author":"Deakin","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022072312084583300_keab795-B24","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10557-009-6205-4","article-title":"Benefits and difficulties in measuring HDL subfractions and human paraoxonase-1 activity during statin treatment","volume":"23","author":"Harangi","year":"2009","journal-title":"Cardiovasc Drugs Ther"},{"key":"2022072312084583300_keab795-B25","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1214\/aos\/1176344136","article-title":"Estimating the dimension of a model","volume":"6","author":"Schwarz","year":"1978","journal-title":"Ann Stat"},{"key":"2022072312084583300_keab795-B26","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3109\/08923973.2013.797993","article-title":"Assessing the relationship of paraoxonase-1 q192r polymorphisms and the severity of lung disease in SM-exposed patients","volume":"35","author":"Golmanesh","year":"2013","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"2022072312084583300_keab795-B27","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1093\/rheumatology\/keaa273","article-title":"High- density lipoprotein function is abnormal in idiopathic inflammatory myopathies","volume":"59","author":"Bae","year":"2020","journal-title":"Rheumatology"},{"key":"2022072312084583300_keab795-B28","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1172\/JCI118359","article-title":"Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein","volume":"96","author":"Watson","year":"1995","journal-title":"J Clin Invest"},{"key":"2022072312084583300_keab795-B29","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1172\/JCI1649","article-title":"Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase","volume":"101","author":"Aviram","year":"1998","journal-title":"J Clin Invest"},{"key":"2022072312084583300_keab795-B30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.atherosclerosis.2011.06.054","article-title":"Paraoxonase 1 (PON1) inhibits monocyte-to-macrophage differentiation","volume":"219","author":"Rosenblat","year":"2011","journal-title":"Atherosclerosis"},{"key":"2022072312084583300_keab795-B31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.atherosclerosis.2013.03.005","article-title":"Paraoxonase 1 (PON1) reduces macrophage inflammatory responses","volume":"228","author":"Aharoni","year":"2013","journal-title":"Atherosclerosis"},{"key":"2022072312084583300_keab795-B32","doi-asserted-by":"crossref","first-page":"14457","DOI":"10.1038\/s41598-018-32780-w","article-title":"Paraoxonase 1 knockout rats have impaired T cell development at the CD4\/CD8 double-negative to double-positive transition stage","volume":"8","author":"Bai","year":"2018","journal-title":"Sci Rep"},{"key":"2022072312084583300_keab795-B33","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/S0024-3205(03)00195-4","article-title":"Serum paraoxonase activity decreases in rheumatoid arthritis","volume":"72","author":"Tanimoto","year":"2003","journal-title":"Life Sci"},{"key":"2022072312084583300_keab795-B34","first-page":"BC01","article-title":"Correlation of paraoxonase status with disease activity score and systemic inflammation in rheumatoid arthritic patients","volume":"10","author":"Bindal","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"2022072312084583300_keab795-B35","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/art.21889","article-title":"Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus","volume":"54","author":"Tripi","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2022072312084583300_keab795-B36","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/art.40499","article-title":"Correlation of high-density lipoprotein-associated paraoxonase 1 activity with systemic inflammation, disease activity, and cardiovascular risk factors in psoriatic disease","volume":"70","author":"Husni","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2022072312084583300_keab795-B37","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1194\/jlr.M400489-JLR200","article-title":"The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status","volume":"46","author":"Rozek","year":"2005","journal-title":"J Lipid Res"},{"key":"2022072312084583300_keab795-B38","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0021-9150(98)00084-7","article-title":"Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response","volume":"139","author":"Feingold","year":"1998","journal-title":"Atherosclerosis"},{"key":"2022072312084583300_keab795-B39","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4103\/1947-2714.103310","article-title":"Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases","volume":"4","author":"Litvinov","year":"2012","journal-title":"N Am J Med Sci"},{"key":"2022072312084583300_keab795-B40","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0891-5849(98)00272-X","article-title":"Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants","volume":"26","author":"Aviram","year":"1999","journal-title":"Free Radic Biol Med"},{"key":"2022072312084583300_keab795-B41","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00408-016-9896-x","article-title":"Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease","volume":"194","author":"Johnson","year":"2016","journal-title":"Lung"},{"key":"2022072312084583300_keab795-B42","first-page":"903","article-title":"Role of endothelial damage in the pathogenesis of interstitial pneumonitis in patients with polymyositis and dermatomyositis","volume":"33","author":"Funauchi","year":"2006","journal-title":"J Rheumatol"},{"key":"2022072312084583300_keab795-B43","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0140-6736(05)61755-2","article-title":"Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation","volume":"349","author":"Mackness","year":"1997","journal-title":"Lancet"},{"key":"2022072312084583300_keab795-B44","doi-asserted-by":"crossref","first-page":"3483427","DOI":"10.1155\/2020\/3483427","article-title":"Lactonase activity, status, and genetic variations of paraoxonase 1 in women with gestational diabetes mellitus","volume":"2020","author":"Zhou","year":"2020","journal-title":"J Diabetes Res"},{"key":"2022072312084583300_keab795-B45","first-page":"449","article-title":"Relationship between paraoxonase-1 genotype, activity, and major adverse cardiovascular events in patients with rheumatoid arthritis receiving tofacitinib","volume":"80","author":"Charles-Schoeman"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab795\/41174259\/keab795.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/6\/2512\/45051867\/keab795.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/6\/2512\/45051867\/keab795.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T12:09:09Z","timestamp":1658578149000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/6\/2512\/6410659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,26]]},"references-count":45,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,10,26]]},"published-print":{"date-parts":[[2022,5,30]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab795","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2021,10,26]]}}}